Mesenchymal stem cells (MSCs) have therapeutic value in many diseases. Mitochondria transfer can promote wound healing and can potentially be applied to the repair of damaged tissue, but the specific mechanisms and regulatory factors involved remain unclear. In this review, we discuss the mechanistic basis of mitochondria transfer and factors that restore mitochondrial function in injured somatic cells.
6 November 2023 in Cardiovascular Drugs and Therapy
Diabetic cardiomyopathy (DCM), a major cause of diabetic mortality, lacks effective therapies. This study investigated the cardioprotective role of Heterophyllin B (HET-B), a natural compound and its underlying mechanisms in DCM. Using streptozotocin-induced DCM mice and high glucose (HG)-treated H9C2/neonatal cardiomyocytes, we assessed cardiac function, mitochondrial homeostasis, and apoptosis. HET-B significantly improved cardiac function, indicated by increased ejection fraction (EF) and fractional shortening (FS). It also reduced cardiomyocyte apoptosis (in vivo/vitro), and ameliorated HG-induced mitochondrial damage, characterized by dysfunction, fragmentation, and excessive reactive oxygen species (ROS) production. HET-B enhanced mitochondrial fusion protein OPA1 expression and reduced Bax/Bcl2, cytochrome C (Cyt C) release and caspase-3 cleavage. Molecular docking and cellular thermal shift assays identified mitochondrial antiviral-signaling protein (MAVS) as a potential target of HET-B. HET-B reversed MAVS downregulation induced by HG/DCM in vitro and in vivo. Importantly, MAVS knockdown via siRNA abolished HET-B's protection against HG-induced apoptosis and mitochondrial damage. Furthermore, HET-B restored HG-impaired autophagic flux, reducing autolysosome accumulation and normalizing LC3-II. Collectively, the natural compound HET-B alleviates diabetic myocardial injury by targeting MAVS to enhance autophagy, maintain mitochondrial homeostasis, and inhibit cardiomyocyte apoptosis, positioning it as a promising therapeutic candidate for DCM.